Lisanti Capital Growth LLC bought a new position in shares of SiBone (NASDAQ:SIBN - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 168,525 shares of the company's stock, valued at approximately $2,364,000. Lisanti Capital Growth LLC owned approximately 0.40% of SiBone as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds have also recently bought and sold shares of SIBN. Silvercrest Asset Management Group LLC raised its stake in shares of SiBone by 21.9% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,953,806 shares of the company's stock valued at $27,392,000 after acquiring an additional 350,970 shares during the period. American Century Companies Inc. increased its holdings in SiBone by 11.0% in the 4th quarter. American Century Companies Inc. now owns 2,378,068 shares of the company's stock valued at $33,341,000 after purchasing an additional 236,167 shares in the last quarter. Marshall Wace LLP increased its holdings in SiBone by 332.5% in the 4th quarter. Marshall Wace LLP now owns 264,523 shares of the company's stock valued at $3,709,000 after purchasing an additional 203,361 shares in the last quarter. Nuveen Asset Management LLC raised its position in SiBone by 17.8% in the fourth quarter. Nuveen Asset Management LLC now owns 1,263,988 shares of the company's stock valued at $17,721,000 after purchasing an additional 190,830 shares during the period. Finally, First Eagle Investment Management LLC acquired a new position in shares of SiBone during the fourth quarter worth about $2,600,000. Hedge funds and other institutional investors own 98.11% of the company's stock.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 target price on shares of SiBone in a research report on Tuesday, May 6th. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price target on shares of SiBone in a report on Tuesday, May 6th. Finally, Truist Financial lifted their price objective on shares of SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Tuesday, May 6th.
Check Out Our Latest Stock Report on SIBN
Insider Transactions at SiBone
In other news, CFO Anshul Maheshwari sold 2,424 shares of the business's stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $19.48, for a total value of $47,219.52. Following the completion of the sale, the chief financial officer directly owned 222,083 shares in the company, valued at approximately $4,326,176.84. The trade was a 1.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Anthony J. Recupero sold 4,147 shares of SiBone stock in a transaction on Friday, May 16th. The stock was sold at an average price of $19.56, for a total transaction of $81,115.32. Following the completion of the transaction, the insider directly owned 282,015 shares of the company's stock, valued at approximately $5,516,213.40. This represents a 1.45% decrease in their position. The disclosure for this sale can be found here. Insiders sold 89,503 shares of company stock valued at $1,643,123 over the last 90 days. Corporate insiders own 3.90% of the company's stock.
SiBone Stock Up 0.7%
Shares of SIBN traded up $0.12 during trading on Wednesday, reaching $18.43. The company's stock had a trading volume of 439,582 shares, compared to its average volume of 393,347. The company has a market cap of $785.49 million, a price-to-earnings ratio of -28.80 and a beta of 0.93. The company has a quick ratio of 7.26, a current ratio of 8.53 and a debt-to-equity ratio of 0.21. The company has a fifty day moving average of $17.57 and a two-hundred day moving average of $16.07. SiBone has a twelve month low of $11.70 and a twelve month high of $20.05.
SiBone (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.09. The firm had revenue of $47.29 million for the quarter, compared to analysts' expectations of $45.13 million. SiBone had a negative net margin of 15.03% and a negative return on equity of 16.00%. On average, sell-side analysts predict that SiBone will post -0.78 EPS for the current fiscal year.
About SiBone
(
Free Report)
SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.
See Also
Before you consider SiBone, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SiBone wasn't on the list.
While SiBone currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
